Latest news with #respiratorydiseases
Globe and Mail
4 days ago
- Business
- Globe and Mail
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 20,000 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 20,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees' acceptance of employment with the Company. The options have an exercise price of $2.29 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16 th of the number of shares subject to the option on each quarterly anniversary of the employee's first day of employment, subject to the employee's continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee's first day of employment, subject to the employee's continued employment on such vesting date. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via an investigational eFlow ® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn: *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Yahoo
6 days ago
- Business
- Yahoo
Verona Pharma plc (VRNA): A Bull Case Theory
We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed's Substack by Patients Capital Management. In this article, we will summarize the bulls' thesis on VRNA. Verona Pharma plc (VRNA)'s share was trading at $91.53 as of 3rd July. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma, a UK-based biopharmaceutical company, is advancing a standout therapeutic with its lead asset, Ohtuvayre, poised to redefine treatment for COPD and related respiratory diseases. The most compelling data point is patient feedback: individuals using Ohtuvayre report feeling noticeably better, which is critical in COPD where managing daily wellbeing matters most. Ohtuvayre's non-steroidal mechanism means it can be safely combined with all existing COPD medications, creating effectively zero competition and addressing a major unmet need by avoiding the downsides of chronic steroid therapies. Beyond COPD, Verona Pharma retains significant upside from potential indications in non-CF bronchiectasis and asthma, which remain largely unpriced in current valuations and could offer meaningful long-term growth—serving as optionality embedded in the investment thesis. Strategically, the company is positioning for partnerships by developing dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations, creating a clear window for larger pharmaceutical companies to engage in due diligence or acquisition discussions. Importantly, Verona Pharma carries no near-term financing overhang, eliminating a common investor concern and making potential deal outcomes even more impactful. Despite a strong rally in the stock, the market still appears to underappreciate Verona Pharma's potential: analysts are currently modeling peak sales of around $2.5 billion, even though the nebulized version alone could realistically reach $4–5 billion. As sell-side estimates adjust quarterly to reflect this upside, the stock is likely to re‐rate. Looking ahead, growing investor conviction and evolving shareholder base could provide deeper support for higher valuation levels. With differentiated clinical efficacy, broad strategic optionality, strong balance sheet, and significant valuation mispricing, Verona Pharma offers a compelling multi-catalyst investment opportunity in respiratory therapeutics. Previously, we covered a on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in May 2025, which highlighted the company's transformation under CEO Richard Francis, strong free cash flow growth, and rising contributions from innovative drugs like Austedo and Uzedy. The company's stock price has been stable with an approximate 0.7% gain since our coverage. This is because the thesis has yet to fully play out but remains valid given Teva's ongoing operational momentum and valuation support. Patients Capital Management shares a similar view on Verona Pharma but emphasizes a more targeted bet on a single asset, Ohtuvayre, with blockbuster potential and strategic optionality in respiratory therapeutics. VRNA isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of VRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-07-2025
- Business
- Yahoo
Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition
We recently published . Verona Pharma plc (NASDAQ:VRNA) is one of the stocks Jim Cramer recently discussed. Verona Pharma plc (NASDAQ:VRNA) is a small biotechnology company that focuses on respiratory diseases. Its shares rocketed by 20.6% in July after pharma giant Merck announced that it would buy the firm for a $10 billion price tag. However, even before the acquisition, Verona Pharma plc (NASDAQ:VRNA)'s shares were up by a strong 80%. The stock has been helped by improving revenue and shrinking losses, which are good performance indicators for upstart biotechnology and pharmaceutical companies. Cramer's comments about Verona Pharma plc (NASDAQ:VRNA) covered Merck's acquisition: 'Yeah, I talked to Rob this morning, really liked this. He thinks he's got about 50 billion dollars worth of new drugs, which would therefore make it so you should stop worrying about the Keytruda patent expiration in 2028. I am with Rob. I think this COPD is a really important, another important franchise for them the alternative use steroids. And we've all be discovering that if you have trouble using steroids, one it becomes less effective over time, and two, the side effects are much worse than people realize. So I think this is a first in class, novel, compound that will make it so. . .I like this acquisition very much.' A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Earlier, the CNBC host had dubbed Verona Pharma plc (NASDAQ:VRNA)'s shares as speculative: 'That stock is a rocket ship. Again, very very speculative, because it loses a lot of money. Does have a couple things in the pipe that people like, but also has a huge amount of insider selling, frankly.' While we acknowledge the potential of VRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
07-07-2025
- Science
- Bloomberg
Wildfire Smoke Brings a Forgotten Danger to the Arctic: Black Carbon
In 2023, the Canada wildfires that incinerated more than 17 million hectares (42 million acres) of boreal forest were so hot they melted the paint on approaching fire trucks and smoldered underground all winter. That heat created vast columns of rising air, carrying dust, volatile organic compounds, and huge quantities of a simple particle with the potential to exacerbate climate change: black carbon. Commonly known as soot, black carbon is a type of pollution formed by the incomplete combustion of fossil fuels or biomass such as trees. It's a risk to human health, having been linked to respiratory and cardiovascular diseases. It's also a potent short-term warming agent. Black carbon absorbs copious heat from the sun and, when it coats a layer of ice or snow, reduces its ability to reflect solar energy back into space.
Associated Press
24-06-2025
- Health
- Associated Press
Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil® (N-acetylcysteine)
MILAN--(BUSINESS WIRE)--Jun 24, 2025-- Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients' lives better, announces the approval by Chinese regulatory authorities and the launch on the Chinese market of the intravenous (IV) formulation of Fluimucil® (N-acetylcysteine). This milestone marks a significant step in the company's commitment to global therapeutic innovation in respiratory diseases, reflecting its dedicated focus on both clinical research and patient care. Already available in several international markets, Fluimucil® IV represents a new option for Chinese patients, where it can provide an important hospital-based therapeutic option for treating respiratory diseases characterized by excessive mucus secretion. The approval in China follows a locally conducted clinical development program, a Phase 1 and a Phase 3 clinical trial that confirmed the drug's safety, tolerability, and efficacy profile. The Phase 1 pharmacokinetics and tolerability study1 of Fluimucil® IV in healthy volunteers, run at the Ruijin Hospital affiliated with the Shanghai Jiao Tong University School of Medicine and led by Prof. Yaozong Yuan, showed that single and multiple 600 mg doses of Fluimucil® IV were well tolerated and free from significant adverse events 2. A pivotal Phase 3 clinical trial3 - started in June 2019 and concluded in February 2021 - involving 333 adult patients with respiratory diseases and abnormal mucus secretions across 28 hospital centers in China, and led by Prof. Jieming Qu, demonstrated that Fluimucil® IV (600 mg, twice daily) was significantly superior to placebo and non-inferior to intravenous ambroxol hydrochloride in reducing sputum viscosity and improving ease of expectoration after 7 days of treatment. The data also demonstrate that the drug is well tolerated 4. ' The approval of Fluimucil® IV in China is a major recognition of the scientific rigor with which we conducted the clinical trials and the quality of our collaboration with local research centers,' said Paola Castellani, Chief Medical Officer and Head of R&D at Zambon. ' We would like to sincerely express our gratitude to patients participating in our clinical studies, as well as to investigators for their commitment. ' ' We are proud to celebrate the 60 th anniversary of Fluimucil® by making its intravenous formulation available in China, confirming the long-standing efficacy of this molecule,' said Giovanni Magnaghi, CEO of Zambon. ' This approval is the result of a joint effort with local scientific communities and reinforces our commitment and sense of responsibility to improving patients' quality of life. ' The intravenous formulation of Fluimucil® will initially be distributed in a selection of Chinese hospitals and represents another step forward in Zambon's expansion strategy in the Chinese market. For further information on Zambon please visit 1Study Details | A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers | 2 Sun J, Zhang X, Wang L, Di Stefano A F D, Zanin V, Magrone P, Yuan Y : Phase I study of the pharmacokinetics and safety of single and multiple doses of intravenous N-acetylcysteine in healthy Chinese subjects: 3Study Details | A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions | 4 Tang W, Zhu D, Wu F, Xu J-F, Yang J-P, Deng Z-P, Chen X-B, Papi A, Qu J-M Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion: View source version on CONTACT: Media Contacts Marco Allegrini, Corporate Communications [email protected] KEYWORD: CHINA EUROPE ITALY ASIA PACIFIC INDUSTRY KEYWORD: HEALTH HOSPITALS OTHER HEALTH OTHER SCIENCE CLINICAL TRIALS SCIENCE PHARMACEUTICAL SOURCE: Zambon Copyright Business Wire 2025. PUB: 06/24/2025 04:00 AM/DISC: 06/24/2025 04:01 AM
